As U.S. calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort

Desperate for answers to the COVID-19 pandemic, the U.S. government has shelled out big money for a stable and reliable supply of key drugs made on U.S. soil. For drugmakers accustomed to offshore manufacturing in cheaper countries, does it make any sense to onshore production to meet U.S. demand?